RxDoctor Payments Data

Camille Ahern, NP

Family · Corpus Christi, TXNPI 1235623075

Payments from drug & device makers

$3,145in general payments, 2019–2025

Across 31 payments — averaging $101.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$772
  • Nevro Corp.$265
  • Corcept Therapeutics$229
  • Lilly USA, LLC$229
  • AbbVie$185
  • Inspire Medical Systems, Inc.$179
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,145 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$3,834
Medicare patients
43
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$48,234
JardianceEmpagliflozin28$44,734
TrulicityDulaglutide13$34,878
Bydureon BciseExenatide Microspheres14$34,350
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$30,161
EliquisApixaban21$28,300
XareltoRivaroxaban11$13,072
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$8,037
Gabapentin116$2,973
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,564
Albuterol Sulfate HfaAlbuterol Sulfate53$2,114
Atorvastatin Calcium153$1,637
Fluticasone Propionate81$1,547
Duloxetine Hcl36$1,336
Omeprazole45$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$772$48,23433 claims
Lilly USA, LLCTrulicity$229$34,87813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →